Strides Pharma Science

Strides Pharma Science EBITDA Margin

The EBITDA Margin of Strides Pharma Science (STAR.NS) as of Nov 22, 2026 is 17.63 %. In the previous year, EBITDA Margin was 15.03 % — a change of 17.27% (higher).

EBITDA Margin

17.63 %

YoY

17.27%

Last updated:

EBITDA Margin of Strides Pharma Science is 2025 17.63 % . EBITDA Margin of Strides Pharma Science was 2024 15.03 % . It decreases by 17.27% higher compared to the previous year.

The Strides Pharma Science EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
14.52 INR
Jan 1, 2019
12.17 INR
Jan 1, 2020
19.89 INR
Jan 1, 2021
19.14 INR
Jan 1, 2022
-0.14 INR
Jan 1, 2023
10.50 INR
Jan 1, 2024
15.03 INR
Jan 1, 2025
17.63 INR
The Strides Pharma Science EBITDA Margin history
YEAREBITDA MarginYoY
17.63 %+17.27%
15.03 %+43.22%
10.50 %-7,774.01%
-0.14 %-100.71%
19.14 %-3.82%
19.89 %+63.48%
12.17 %-16.21%
14.52 %-24.98%
19.36 %+31.42%
14.73 %-29.29%
20.83 %+9.08%
19.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd. generates revenue through the development, manufacturing, and distribution of IP-led generics and bio-pharmaceutical products across its Pharmaceutical and Bio-pharmaceutical segments. The company serves global markets including Africa, Australia, Asia (excluding India), North America, Europe, India, and Others, offering niche pharmaceutical products in various dosage forms such as liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. Its manufacturing units in Bengaluru, Puducherry, Chennai, Singapore, Milan, Florida, and Nairobi produce anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drugs, alongside soft gelatin capsules. The firm's revenue streams are derived from the sale of its IP-led niche pharmaceutical products to healthcare providers, distributors, and global pharmaceutical companies operating in the specified geographical segments. Key product categories include anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, which are distributed through its global manufacturing network. The company's focus on specialized drug segments ensures consistent demand from healthcare systems and institutions managing infectious diseases. Strides Pharma Science Ltd. targets healthcare institutions, distributors, and pharmaceutical companies in regions such as North America, Europe, India, and Africa, where infectious disease management requires specialized treatments. Its manufacturing presence in multiple countries supports direct market access and cost efficiency, enabling the delivery of affordable pharmaceutical solutions. The company's product portfolio emphasizes high-demand therapeutic areas, aligning with global health priorities for infectious disease treatment. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

EBITDA Margin of Strides Pharma Science is 17.63 % in 2025.

EBITDA Margin of Strides Pharma Science changed from 15.03 % to 17.63 %, representing a 17.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Strides Pharma Science with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Strides Pharma Science

All Key Metrics — Strides Pharma Science